Cidara Therapeutics, Inc. CDTX 深 沪
等待开盘 05-18 09:30:00 美东时间
221.38
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 221.38
- 总市值 69.74亿
- 52周最高 221.42
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 15.22
- 委 比 0.00%
- 总股本 3150.43万
- 历史最高 382.60
- 量 比 0
- 振 幅 0.00%
- 历史最低 8.00
- 每 手 1
- 风险率 68.45%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Strong biopharma dealmaking market set to continue
The strong trend in pharma and biotech dealmaking, which has been ongoing for several years, should continue according to experts. Speaking at the FT US Pharma and Biotech Summit in New York, Eric Tok...
05-15 01:41
默沙东完成收购产生大额费用 上调2026年业绩指引推进收购计划
经济观察网 默沙东近期披露收购进展及最新业绩指引，已完成对Cidara Therapeutics收购，同时上调2026年营收及每股收益预期。 业务进展情况 近期...
05-06 01:06
Merck Swings To Quarterly Loss On Cidara Deal
Merck Q1 2026 results show oncology-led growth, vaccine weakness, and raised guidance after beating sales and loss estimates.
05-01 01:10
Merck Q1 earnings beat lifts shares; 2026 guidance narrowed
Merck (MRK) was up around 5% premarket on Thursday after it beat top- and bottom-line estimates for Q1 and issued a narrowed outlook for 2026. The Rahway, New Jersey–based company adjusted its guidanc...
04-30 18:59
Merck & Co Inc Stock (MRK) Moved Up by 3.18% on Apr 8: Facts Behind the Movement
• Enlicitide Phase 3 results show significant LDL reduction and safety. • Keytruda approved in EU for platinum-resistant ovarian cancer. • Merck acquired Terns Pharmaceuticals to strengthen pipeline.
04-08 18:15
UPDATE 3-Merck braces for Keytruda patent loss with $6.7 billion Terns bet
UPDATE 3-Merck braces for Keytruda patent loss with $6.7 billion Terns bet Rewrites throughout, adds Merck's shares in paragraph 4, adds analyst comments in paragraphs 8, 13-16 March 25 (Reuters) - Merck MRK.N said on Wednesday it would buy biotech Terns Pharma TERN.O for $6.7 billion, as the drugma
03-25 18:54
Merck Nears $6 Billion Deal To Buy Terns Pharma: Report
Merck is reportedly nearing a $6 billion acquisition of Terns Pharmaceuticals to strengthen its oncology pipeline ahead of Keytruda's patent expiry.
03-25 17:38
UPDATE 3-Merck to create separate cancer business as Keytruda patent loss looms
UPDATE 3-Merck to create separate cancer business as Keytruda patent loss looms Adds details and background in paragraphs 6-7 Feb 23 (Reuters) - Merck MRK.N said on Monday it would split its human-health business into two units, creating a division for its cancer franchise led by blockbuster drug Ke
02-23 19:34
UPDATE 2-Merck's 2026 outlook clouds upbeat fourth-quarter results
UPDATE 2-Merck's 2026 outlook clouds upbeat fourth-quarter results Co expects 2026 sales of $65.5 bln-$67 bln vs analysts' estimate $67.6 bln Reports Q4 sales of $16.4 bln, with Keytruda contributing $8.37 bln CEO Davis says still on the lookout for deals Adds analyst comments in paragraphs 5 and 10
02-03 19:40
